Home » China Approves Early Stage Trial of Pfizer and BioNTech’s COVID-19 Vaccine
China Approves Early Stage Trial of Pfizer and BioNTech’s COVID-19 Vaccine
China’s National Medical Products Administration has approved a phase 1 trial of Pfizer and BioNTech’s mRNA-based COVID-19 vaccine candidate BNT162b1.
The trial will be conducted by Fosun Pharma, which entered into a collaboration agreement with BioNTech in March to develop and commercialize the vaccine in China. Fosun said it will initiate the trial “as soon as possible.”
The FDA granted BNT162b1 a fast track review designation earlier this week along with their other mRNA vaccine candidate BNT162b2.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May